Sanofi ADR Company Insiders
SNY Stock | USD 48.60 0.94 1.90% |
Slightly above 60% of Sanofi ADR's corporate insiders are selling. The analysis of insiders' sentiment of trading Sanofi ADR stock suggests that many insiders are alarmed at this time. Sanofi ADR employs about 86.1 K people. The company is managed by 59 executives with a total tenure of roughly 489 years, averaging almost 8.0 years of service per executive, having 1459.12 employees per reported executive.
Olivier Brandicourt CEO CEO, Director and Member of Strategy Committee |
Serge Weinberg Chairman Chairman, Interim CEO, Chairman of Appointments and Governance Committee and Chairman of Strategy Committee |
Sanofi ADR's Insider Buying Vs Selling
40
Selling | Buying |
Latest Trades
2023-07-10 | Daniel S. Goldman | Disposed @ 51.83 | |||
2023-02-27 | Daniel S. Goldman | Disposed @ 47.85 | |||
2022-05-27 | Earl Blumenauer | Acquired @ 55.15 | |||
2022-03-16 | John H. Rutherford | Disposed @ 51.9 | |||
2021-08-02 | Sanofi | Acquired 66667 @ 15 | View |
Monitoring Sanofi ADR's insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Acquired vs Disposed
Filed vs Not Filed
Insider sentiment refers to the collective sentiment or feeling of Sanofi ADR's insiders - typically its officers, directors, and beneficial owners holding more than a certain percentage of the company's stock - about the future prospects of Sanofi ADR. This sentiment is often gauged based on the trading activities of these insiders. If insiders are purchasing more shares of their own company, it may be interpreted as a bullish sentiment, indicating that they believe Sanofi ADR's stock will rise in value. Conversely, if insiders are selling shares, it might be seen as bearish, suggesting they expect the stock price to drop.
Sanofi |
Sanofi ADR's Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Sanofi ADR's future performance. Based on our forecasts, it is anticipated that Sanofi will maintain a workforce of slightly above 86090 employees by April 2024.Sanofi ADR's latest congressional trading
Congressional trading in companies like Sanofi ADR, is subject to rigorous scrutiny to prevent conflicts of interest and insider trading. This is governed by multiple SEC regulations which were established to foster transparency and deter members of Congress from leveraging non-public information for personal gain. This oversight helps maintain public trust and ensures that investments in Sanofi ADR by those in governmental positions are based on the same information available to the general public.
2023-07-10 | Representative Daniel Goldman | Disposed $15K to $50K | Verify | ||
2022-05-27 | Representative Earl Blumenauer | Acquired $15K to $50K | Verify | ||
2022-03-16 | Representative John Rutherford | Disposed Under $15K | Verify | ||
2020-03-19 | Representative Greg Gianforte | Acquired Under $15K | Verify | ||
2017-06-15 | Senator Patty Murray | Acquired Under $15K | Verify |
Sanofi ADR Management Team Effectiveness
The company has Return on Asset of 0.0454 % which means that on every $100 spent on assets, it made $0.0454 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.0727 %, implying that it generated $0.0727 on every 100 dollars invested. Sanofi ADR's management efficiency ratios could be used to measure how well Sanofi ADR manages its routine affairs as well as how well it operates its assets and liabilities. Return On Capital Employed is likely to rise to 0.17 in 2024. Return On Assets is likely to rise to 0.08 in 2024. At this time, Sanofi ADR's Non Currrent Assets Other are fairly stable compared to the past year. Intangible Assets is likely to rise to about 77.3 B in 2024, whereas Total Assets are likely to drop slightly above 88.2 B in 2024.Common Stock Shares Outstanding is likely to rise to about 1.3 B in 2024, whereas Net Income Applicable To Common Shares is likely to drop slightly above 5.9 B in 2024.
Sanofi ADR Workforce Comparison
Sanofi ADR is currently regarded as top stock in number of employees category among related companies. The total workforce of Health Care industry is at this time estimated at about 2.98 Million. Sanofi ADR holds roughly 86,088 in number of employees claiming about 2.89% of equities under Health Care industry.
Sanofi ADR Profit Margins
The company has Net Profit Margin of 0.12 %, which implies that it may need a different competitive strategy as even a very small decline in it revenue may erase profits and result in a net loss. This is way below average. In the same way, it shows Net Operating Margin of 0.07 %, which entails that for every 100 dollars of revenue, it generated $0.07 of operating income.Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
---|---|---|---|---|---|---|---|---|---|
Gross Profit Margin | 0.79 | 0.6152 |
|
| |||||
Net Profit Margin | 0.12 | 0.1254 |
|
| |||||
Operating Profit Margin | 0.22 | 0.2132 |
|
| |||||
Pretax Profit Margin | 0.21 | 0.1661 |
|
| |||||
Return On Assets | 0.0773 | 0.0427 |
|
| |||||
Return On Equity | 0.13 | 0.0729 |
|
|
Sanofi ADR Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. Sanofi ADR Price Series Summation is a cross summation of Sanofi ADR price series and its benchmark/peer.
Sanofi ADR Notable Stakeholders
A Sanofi ADR stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Sanofi ADR often face trade-offs trying to please all of them. Sanofi ADR's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Sanofi ADR's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Olivier Brandicourt | CEO, Director and Member of Strategy Committee | Profile | |
Serge Weinberg | Chairman, Interim CEO, Chairman of Appointments and Governance Committee and Chairman of Strategy Committee | Profile | |
Dominique Carouge | Executive Vice President - Head of Business Transformation Member of the Executive Committee | Profile | |
Pascale Witz | Executive Vice President - Global Divisions & Strategic Commercial Development, Member of the Executive Committee and the Global Leadership Team | Profile | |
Dieter Weinand | Executive Vice President Member of the Executive Board | Profile | |
Sebastien Martel | Vice President - Investor Relations and Member of the Global Leadership Team | Profile | |
George Grofik | Vice President of Investor Relations | Profile | |
John Reed | President - Global Research & Development, Member of the Executive Committee | Profile | |
Caroline Luscombe | Executive Vice President of Human Resources, Member of the Executive Committee | Profile | |
JeanBaptiste Chatillon | CFO, Executive Vice President Member of the Executive Committee | Profile | |
Jerome Contamine | Executive Vice President - CFO, Member of the Executive Committee and Global Leadership Team | Profile | |
Suresh Kumar | Executive Vice President - External Affairs, Member of the Executive Committee and Global Leadership Team | Profile | |
Kathleen Tregoning | Executive Vice President External Affairs; Member of the Executive Committee | Profile | |
William Sibold | Executive Vice President Sanofi Genzyme; Member of the Executive Committee | Profile | |
Peter Guenter | Executive Vice President - Global Commercial Operations, Member of the Executive Committee and the Global Leadership Team | Profile | |
David Loew | Member of the Global LeaderShip Team, Senior Vice President - Commercial Operations Europe | Profile | |
Muzammil Mansuri | Executive Vice President Strategy & Business Development, Member of the Executive Committee and the Senior Leadership Team | Profile | |
Elias Zerhouni | President - Global Research & Development, Member of the Executive Committee and the Global Leadership Team | Profile | |
Ameet Nathwani | Executive Vice President Group Chief Medical Officer, Member of the Executive Committee | Profile | |
Philippe Luscan | Senior Vice President - Industrial Affairs, Member of the Executive Committee and the Global Leadership Team | Profile | |
Roberto Pucci | Senior Vice President - Human Resources, Member of the Executive Committee and the Global Leadership Team | Profile | |
DavidAlexandre Gros | Executive Vice President Chief Strategy Officer and Member of the Executive Committee | Profile | |
Olivier Charmeil | Senior Vice President - Vaccines, Member of the Executive Committee and Global Leadership Team | Profile | |
Stefan Oelrich | Executive Vice President - Diabetes & Cardiovascular, Member of the Executive Committee | Profile | |
Carsten Hellmann | Executive Vice President - Animal Health and Member of the Global Leadership Team | Profile | |
David Meeker | Member of the Executive Board and Executive Vice President - Genzyme and Member of the Global Leadership Team | Profile | |
Alan Main | Executive Vice President Consumer Healthcare; Member of the Executive Committee | Profile | |
Karen Linehan | Executive VP of Legal Affairs and General Counsel | Profile | |
Emmanuel Babeau | Independent Director | Profile | |
Fabienne Lecorvaisier | Director | Profile | |
Klaus Pohle | Independent Director | Profile | |
Bernard Charles | Independent Director | Profile | |
Melanie Lee | Independent Director | Profile | |
Christophe Babule | Director | Profile | |
Bonnie Bassler | Director | Profile | |
Thomas Suedhof | Independent Director | Profile | |
Laurent Attal | Director | Profile | |
JeanRene Fourtou | Independent Director | Profile | |
Christian Mulliez | Director | Profile | |
Robert Castaigne | Independent Director | Profile | |
Uwe Bicker | Independent Director | Profile | |
Claudie Haignere | Independent Director | Profile | |
Diane Souza | Independent Director | Profile | |
Carole Piwnica | Independent Director | Profile | |
Igor Landau | Director | Profile | |
Patrick Kron | Independent Director | Profile | |
Gerard Kemmel | Independent Director | Profile | |
SuetFern Lee | Independent Director | Profile | |
Suet Lee | Independent Director | Profile | |
Roy Papatheodorou | Executive Counsel | Profile | |
Eva SchaeferJansen | Head Relations | Profile | |
Madeleine Roach | Executive Operations | Profile | |
Pierre Chancel | Senior Marketing | Profile | |
Josephine Fubara | Chief Care | Profile | |
Laurent Gilhodes | Principal Accounting | Profile | |
Josep Catlla | Head Communications | Profile | |
Paul Hudson | CEO Director | Profile | |
Bruno Mnard | Chief officer | Profile | |
Dante Beccaria | Global VP | Profile |
About Sanofi ADR Management Performance
The success or failure of an entity such as Sanofi ADR often depends on how effective the management is. Sanofi ADR management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Sanofi management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Sanofi management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last Reported | Projected for 2024 | ||
Return On Capital Employed | 0.09 | 0.17 | |
Return On Assets | 0.04 | 0.08 | |
Return On Equity | 0.07 | 0.13 |
The data published in Sanofi ADR's official financial statements usually reflect Sanofi ADR's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Sanofi ADR. For example, before you start analyzing numbers published by Sanofi accountants, it's critical to develop an understanding of what Sanofi ADR's liquidity, profitability, and earnings quality are in the context of the Pharmaceuticals space in which it operates.
Please note, the presentation of Sanofi ADR's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Sanofi ADR's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Sanofi ADR's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Sanofi ADR. Please utilize our Beneish M Score to check the likelihood of Sanofi ADR's management manipulating its earnings.
Sanofi ADR Workforce Analysis
Traditionally, organizations such as Sanofi ADR use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Sanofi ADR within its industry.Sanofi ADR Manpower Efficiency
Return on Sanofi ADR Manpower
Revenue Per Employee | 500.3K | |
Revenue Per Executive | 730M | |
Net Income Per Employee | 62.7K | |
Net Income Per Executive | 91.5M | |
Working Capital Per Employee | 75.1K | |
Working Capital Per Executive | 109.5M |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sanofi ADR. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. For more information on how to buy Sanofi Stock please use our How to Invest in Sanofi ADR guide.You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.
Complementary Tools for Sanofi Stock analysis
When running Sanofi ADR's price analysis, check to measure Sanofi ADR's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sanofi ADR is operating at the current time. Most of Sanofi ADR's value examination focuses on studying past and present price action to predict the probability of Sanofi ADR's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sanofi ADR's price. Additionally, you may evaluate how the addition of Sanofi ADR to your portfolios can decrease your overall portfolio volatility.
Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
CEOs Directory Screen CEOs from public companies around the world | |
Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
Transaction History View history of all your transactions and understand their impact on performance | |
Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes |
Is Sanofi ADR's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sanofi ADR. If investors know Sanofi will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sanofi ADR listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.217 | Dividend Share 3.76 | Earnings Share 2.33 | Revenue Per Share 18.388 | Quarterly Revenue Growth 0.029 |
The market value of Sanofi ADR is measured differently than its book value, which is the value of Sanofi that is recorded on the company's balance sheet. Investors also form their own opinion of Sanofi ADR's value that differs from its market value or its book value, called intrinsic value, which is Sanofi ADR's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sanofi ADR's market value can be influenced by many factors that don't directly affect Sanofi ADR's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sanofi ADR's value and its price as these two are different measures arrived at by different means. Investors typically determine if Sanofi ADR is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sanofi ADR's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.